Your browser is no longer supported. Please, upgrade your browser.
Dyne Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own14.30% Shs Outstand51.22M Perf Week0.50%
Market Cap829.15M Forward P/E- EPS next Y-3.01 Insider Trans0.00% Shs Float49.76M Perf Month-2.90%
Income-97.50M PEG- EPS next Q-0.65 Inst Own98.44% Short Float3.02% Perf Quarter-25.39%
Sales- P/S- EPS this Y-286.80% Inst Trans2.15% Short Ratio5.56 Perf Half Y-0.06%
Book/sh8.84 P/B1.82 EPS next Y-22.40% ROA-23.00% Target Price- Perf Year-
Cash/sh8.46 P/C1.90 EPS next 5Y- ROE-23.80% 52W Range13.50 - 32.31 Perf YTD-23.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.18% Beta-
Dividend %- Quick Ratio31.70 Sales past 5Y- Gross Margin- 52W Low19.26% ATR0.86
Employees71 Current Ratio31.70 Sales Q/Q- Oper. Margin- RSI (14)42.46 Volatility5.52% 5.28%
OptionableYes Debt/Eq0.00 EPS Q/Q-51.10% Profit Margin- Rel Volume0.30 Prev Close16.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume270.22K Price16.10
Recom1.50 SMA20-1.25% SMA50-9.64% SMA200-15.35% Volume81,297 Change-1.11%
Oct-12-20Initiated Stifel Buy $29
Oct-12-20Initiated Piper Sandler Overweight $34
Oct-12-20Initiated JP Morgan Overweight $27
Oct-12-20Initiated Jefferies Buy $47
Aug-05-21 07:30AM  
Jul-26-21 03:00AM  
Jun-25-21 07:30AM  
Jun-02-21 04:05PM  
May-26-21 07:30AM  
May-14-21 02:44PM  
May-06-21 07:29AM  
Apr-27-21 04:35PM  
Mar-04-21 07:35AM  
Feb-08-21 07:30AM  
Jan-27-21 01:13AM  
Jan-20-21 08:05PM  
Jan-10-21 03:00PM  
Jan-05-21 07:30AM  
Dec-08-20 10:17AM  
Nov-09-20 07:30AM  
Nov-05-20 07:35AM  
Oct-09-20 03:41PM  
Sep-21-20 04:05PM  
Sep-16-20 07:00PM  
Dec-13-19 03:38PM  
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.